WO2019227342A1 - 一种长链多肽的纯化方法 - Google Patents

一种长链多肽的纯化方法 Download PDF

Info

Publication number
WO2019227342A1
WO2019227342A1 PCT/CN2018/089034 CN2018089034W WO2019227342A1 WO 2019227342 A1 WO2019227342 A1 WO 2019227342A1 CN 2018089034 W CN2018089034 W CN 2018089034W WO 2019227342 A1 WO2019227342 A1 WO 2019227342A1
Authority
WO
WIPO (PCT)
Prior art keywords
phase
column
packing
purification
salt
Prior art date
Application number
PCT/CN2018/089034
Other languages
English (en)
French (fr)
Inventor
尹传龙
宓鹏程
陶安进
袁建成
Original Assignee
深圳翰宇药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳翰宇药业股份有限公司 filed Critical 深圳翰宇药业股份有限公司
Priority to CN201880000485.0A priority Critical patent/CN110785427B/zh
Priority to US15/733,862 priority patent/US11312744B2/en
Priority to EP18921212.9A priority patent/EP3805246A4/en
Priority to PCT/CN2018/089034 priority patent/WO2019227342A1/zh
Publication of WO2019227342A1 publication Critical patent/WO2019227342A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Definitions

  • the invention relates to the field of pharmaceutical analysis, and in particular to a method for purifying a long-chain polypeptide drug.
  • Ularitide is a sodium urinary excretion cyclic peptide developed by Cardiorentis (AG). It consists of 32 amino acid residues. It was originally isolated from urine in 1988 by Schulz-Knappe et al. A kind of renal natriuretic peptide belonging to the atrial natriuretic peptide (ANP) family, which is mainly used for the treatment of acute heart failure.
  • a kind of renal natriuretic peptide belonging to the atrial natriuretic peptide (ANP) family which is mainly used for the treatment of acute heart failure.
  • the molecular formula is as follows:
  • Heart failure is divided into acute heart failure and chronic heart failure.
  • emergency medical treatments for acute heart failure in the United States.
  • About 15 to 20% of patients with acute heart failure are first diagnosed heart failure, most of them are the original exacerbation of heart failure, all diseases that cause chronic heart failure can cause acute heart failure.
  • chronic heart failure decompensation and acute heart failure episodes have also become the main cause of hospitalization for patients with heart failure.
  • the total incidence of heart failure each year is 0.23% to 0.27%.
  • Acute heart failure has a poor prognosis, with a hospital mortality rate of 3%, a 60-day mortality rate of 9.6%, and 3-year and 5-year mortality rates are as high as 30% and 60%, respectively.
  • Acute myocardial infarction has a higher mortality rate for acute heart failure.
  • the in-hospital mortality rate of patients with acute pulmonary edema is 12%, and the one-year mortality rate is 30%. Therefore, the market prospect of uramide is broad.
  • the existing peptide purification is mainly prepared by a high-performance liquid preparation system.
  • the organic phase is acetonitrile, methanol, etc., and the amount of use is large, and the waste liquid discharge is also large. Waste liquid recovery is difficult to handle, and the danger is also large.
  • the waste liquid discharge will be larger, the purification cycle will be correspondingly longer, and the enterprise cost will be larger.
  • Environmental protection, safety, and cost issues have restricted the development of pharmaceutical companies, and a purification method that reduces enterprise costs and waste liquid discharge is urgently needed to minimize the danger in the storage of organic waste liquid.
  • Uralide is mainly used for acute heart failure, so quality is particularly important.
  • Uralide peptides have a long peptide sequence, and there is one more step of oxidation in the middle. There are more impurities.
  • the existing peptide drugs have higher purity requirements, the better, most of which require purity greater than 99%.
  • the control requires less than 0.10% of impurities.
  • Traditional purification process to reach this standard generally requires two steps of purification, one step of salt conversion, the yield will be particularly low; labor costs, environmental costs and product costs will be large.
  • the purification of peptides is mainly through reversed-phase chromatography.
  • the stationary phases used generally include C18, C8, C4, C1, etc.
  • polymer fillers for purification or even other reversed-phase fillers but no matter what is used
  • the type of packing has basically no change in the purification process. There are two basic processes. One is a column prepared by high-pressure packing of the same kind of packing. The column length is generally about 25 cm and the particle size is mostly 10 ⁇ m. Then it is purified by different chromatography conditions. Then the unqualified parts are recovered and finally qualified products are obtained. The other is a preparative column packed with different types of packing under high pressure. The column length is about 25 cm and the particle size is generally 10 ⁇ m.
  • the invention provides a new purification method, which can improve the purity of the product, the purity is greater than 99%, the single impurity is less than 0.10%, and the cost and environmental protection pressure can be greatly reduced.
  • the invention provides a new purification method, which is different from the traditional purification method, and can make up for the disadvantages of the traditional purification method that the cost of recycling is increased, the cycle is longer, the waste liquid is discharged, the yield is greatly improved, and it is easy to scale up the production.
  • One aspect of the present invention provides a method for purifying a long-chain polypeptide, which includes the following steps:
  • Step 1) The column packing is selected from C18 silica packing, C8 silica packing, C4 silica packing and polymer packing; the length of the upstream chromatography column is 8-20cm; the length of the downstream chromatography column is 8-20cm;
  • A1 phase is a buffered salt solution with a pH value of 2-3.
  • the buffered salt solution is one of ammonium sulfate, potassium dihydrogen phosphate, disodium hydrogen phosphate, and dipotassium hydrogen phosphate.
  • the B phase is an organic phase, and the organic phase is acetonitrile, methanol, isopropanol, and ethanol; the amount and concentration of the buffer salt substance is 20 mM to 150 mM; the detection wavelength is 230 nm;
  • Step 1) includes gradient elution: A1%: 95% -55%, B%: 5% -45%, elution time is 30-120 minutes; during the elution process, when the effluent peak of the upstream column is When the impurity peak is discarded, the corresponding mobile phase is discarded.
  • the effluent peak of the upstream column is the target peak
  • the chromatographic pump connected to the tee mixer set in the middle of the upstream and downstream columns is started, and 10% purified water is input to reduce the mobile phase
  • step 2) as a trans-salt:
  • Step 2) Use the upstream chromatographic column in step 1) for salt conversion.
  • the A2 phase is a 0.05% -0.2% acetic acid aqueous solution by volume.
  • the B phase is an organic phase.
  • the organic phase is acetonitrile, methanol, isopropanol, and ethanol. ; Detection wavelength: 230nm;
  • Step 2) includes: loading the target peak product obtained in step 1); washing with 95% A2 and 5% B for 15-30min for desalting;
  • the long-chain polypeptide is selected from a long-chain polypeptide of 35 amino acids or more, and is preferably uralitide, liraglutide, samoglutide, thymus, fabaxin, apaparatide, lysine Cilacitide and others.
  • the upstream chromatographic column packing is a 10 ⁇ m C18 silica gel packing with a length of 10-15 cm
  • the second chromatographic column is a 5 ⁇ m C18 silica gel packing with a length of 10-15 cm.
  • step 1) includes elution in a gradient: A1%: 85% -65%, B%: 15% -55%, and an elution time of 50-70 minutes.
  • the pH value of the A1 phase is 2.2-2.8.
  • the A2 phase is an ammonium acetate solution with a volume ratio of 0.1% to 0.4%.
  • step 2) is desalted by washing with 95% A2 and 5% B for 15-30 minutes.
  • step 2) performs the salt transfer with gradient elution, A2%: 85% -65%, B%: 15% -35%, elution for 10-30min, and collecting the target product.
  • a new purification method Two different types of chromatographic columns are installed at the same time.
  • the first preparative column is 10 ⁇ m C18 and the second preparative column is 5 ⁇ m C18.
  • the column length is 10- 15cm, then connected in series.
  • the purification of uraripeptide the larger particle size comes first, and the smaller particle size comes first. Then the uralide peptide oxidation solution is loaded and purified. .
  • a new method for purifying uralipide Two different types of packing are used to fill two preparation columns, and then connected in series, one step purification and one salt transfer.
  • the first step is to buffer the salt solution at a certain concentration and pH as A1.
  • Phase using acetonitrile as phase B, the second step with a certain concentration of acetic acid as phase A2, acetonitrile as phase B, gradient elution HPLC method to transfer the salt, the solution was collected and lyophilized to obtain uraridide acetate.
  • Uralide peptides have long peptide chains, which produce a lot of impurities during synthesis, and contain amino acids that are easily isomerized during the synthesis process, such as Ser, resulting in isomer impurities in the crude peptide.
  • the present invention can purify two different types of packings in series, and utilize the characteristics of two different types of packings and different separation capabilities.
  • the target peak does not flow out of the preparation system and enters the downstream.
  • the third pump is used to input 10% purified water to reduce the organic phase ratio, and then connected to the second preparation column for secondary separation. The original two-step purification process was required, and the one-step purification was completed.
  • the intermediate process was also reduced. Precipitation, denaturation caused by storage of intermediates, and other risks that affect product quality, save time and effort.
  • This purification method can well separate and remove isomer impurities and other difficult-to-separate impurities in crude peptides, and then use reversed-phase HPLC The method was converted to acetate, which ultimately improved the yield and purity of the product, and at the same time solved the shortcomings of traditional purification methods, which are time-consuming, labor-intensive, and heavy, and easy to operate, which is conducive to large-scale preparation. .
  • the amount of the buffer salt substance in the mobile phase A1 of the HPLC method of the present invention is 20 mM to 150 mM, and the volume ratio of the acetic acid in the mobile phase A2 is 0.05% to 0.2%.
  • the pH in the mobile phase A1 of the HPLC method according to the present invention ranges from 2.2 to 2.8.
  • the buffer salt is one or more of ammonium sulfate, potassium dihydrogen phosphate, disodium hydrogen phosphate, and dipotassium hydrogen phosphate.
  • the acetonitrile of the mobile phase B of the HPLC method according to the present invention is purified.
  • the stationary phase of the purification HPLC method according to the present invention is octadecyl, and the particle diameter is 5 ⁇ m and 10 ⁇ m.
  • the tandem preparation column purification uses two kinds of packing with different separation capabilities for purification. Under the original column length, two separations are achieved, reducing the number of recovery times, reducing the cycle, reducing the amount of organic phase used, and simple operation. Easy to enlarge, the most important thing is to save time and labor, and save costs. Especially for peptides with a peptide length greater than 35, the effect will be more prominent due to the multiple steps of purification and recovery, mainly because the longer the peptide chain, the more hydrophobic it is. The amount of organic phase is increased during elution, and the amount of waste liquid is particularly large due to multiple recovery.
  • the implementation example is as follows:
  • the purification scale includes the following specifications: 5cm ⁇ 25cm (column diameter ⁇ length), 10cm ⁇ 25cm, 15cm ⁇ 25cm.
  • Figure 1 shows the results of the linear crude peptide mass spectrum.
  • Figure 2 shows the results of sperm peptide mass spectrometry.
  • FIG. 3 shows the HPLC results of the pure product of Example 1.
  • FIG. 4 shows the HPLC results of the pure product of Example 2.
  • FIG. 5 shows the HPLC results of the pure product of Example 3.
  • FIG. 6 shows the HPLC results of the pure product of Example 4.
  • Figure 7 shows the HPLC results of the pure product of Example 5.
  • Figure 8 shows the HPLC results of the pure product of Example 6.
  • FIG. 9 shows the HPLC results of the pure product of Example 7.
  • FIG 10 shows the HPLC results of the pure product of Example 8.
  • FIG. 11 shows the HPLC results of the pure product of Example 9.
  • Chromatographic column A stationary phase chromatographic column with a particle size of 10 ⁇ m of C18 silica gel packing was used as the preparation column 1. The diameter and length of the column were: 5 cm ⁇ 10 cm. A C18 silica packed 5 ⁇ m particle size stationary phase chromatographic column was used as the preparation column 2. The diameter and length of the column were: 5 cm ⁇ 15 cm.
  • the first step mobile phase: A1 phase: 50mmol / L potassium dihydrogen phosphate solution was adjusted to pH 2.2 with phosphoric acid; phase B: chromatographically pure acetonitrile. Flow rate: 60-80ml / min. Detection wavelength: 230nm.
  • the uraridide linear crude peptide solution was loaded and eluted in the following gradient: A1%: 85% -65%, B%: 15% -35%, and a total elution of 50-70min.
  • the impurity peak waste liquid is treated, and when the target product is out of the peak, it is diluted online by a third pump connected to the tee mixer to enter column 2 for secondary separation.
  • the mobile phase diluted online was purified water with a flow rate of 5-20 ml / min.
  • the target product that meets the quality requirements enters the second step.
  • the second step mobile phase: A2 phase: 0.1-0.4% ammonium acetate solution, pH 6.5-7.0, phase B: chromatographically pure acetonitrile. Flow rate: 60-80ml / min. Detection wavelength: 230nm.
  • Chromatographic column A stationary phase chromatographic column with a particle size of 10 ⁇ m on a C18 silica gel packing was used as the preparation column 1. The diameter and length of the column were: 10 cm ⁇ 15 cm. A C18 silica packed 5 ⁇ m particle size stationary phase chromatography column was used as the preparative column 2. The diameter and length of the column were: 10 cm ⁇ 10 cm.
  • the first step mobile phase: A1 phase: 150mmol / L potassium dihydrogen phosphate solution was adjusted to pH 2.5 with phosphoric acid; phase B: chromatographically pure acetonitrile. Flow rate: 200-220ml / min. Detection wavelength: 230nm.
  • the uraritide linear crude peptide solution was loaded and eluted in the following gradient: A1%: 85% -65%, B%: 15% -35%, and a total elution of 50-70min.
  • the impurity peak waste liquid is treated, and when the target product is out of the peak, it is diluted online by a third pump connected to the tee mixer to enter column 2 for secondary separation.
  • the mobile phase diluted online was purified water with a flow rate of 20-50 ml / min.
  • the product that meets the quality standards enters the second step.
  • the second step mobile phase: A2 phase: 0.1-0.4% ammonium acetate solution, pH 6.5-7.0, phase B: chromatographically pure acetonitrile. Flow rate: 200-220ml / min. Detection wavelength: 230nm.
  • Chromatographic column A stationary phase chromatographic column with a particle size of 10 ⁇ m on a C18 silica gel packing was used as the preparation column 1. The diameter and length of the column were 15 cm ⁇ 15 cm. A C18 silica gel 5 ⁇ m particle size stationary phase chromatography column was used as the preparative column 2. The diameter and length of the column were 15 cm ⁇ 10 cm.
  • the first step mobile phase: A1 phase: 100mmol / L ammonium sulfate solution was adjusted to pH 2.8 with phosphoric acid; phase B: chromatographically pure acetonitrile. Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • the uraridide linear crude peptide solution was loaded and eluted in the following gradient: A1%: 85% -65%, B%: 15% -35%, and a total elution of 50-70min.
  • the impurity peak waste liquid is treated, and when the target product is out of the peak, it is diluted online by a third pump connected to the tee mixer to enter column 2 for secondary separation.
  • the mobile phase diluted online was purified water with a flow rate of 45-100 ml / min.
  • the product that meets the quality requirements after cyclic purification is entered into the second step.
  • the second step mobile phase: A2 phase: 0.1-0.4% ammonium acetate solution, pH 6.5-7.0, phase B: chromatographically pure acetonitrile. Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • Chromatographic column A stationary phase chromatographic column with a particle size of 10 ⁇ m on a C18 silica gel packing was used as the preparation column 1. The diameter and length of the column were 15 cm ⁇ 25 cm.
  • the first step mobile phase: A1 phase: 100mmol / L ammonium sulfate solution was adjusted to pH 2.8 with phosphoric acid; phase B: chromatographically pure acetonitrile. Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • the uraridide linear crude peptide solution was loaded and eluted in the following gradient: A1%: 85% -65%, B%: 15% -35%, and a total elution of 50-70min.
  • the products that meet the quality standards enter the second step.
  • the second step mobile phase: A2 phase: 0.1-0.4% ammonium acetate solution, pH 6.5-7.0, phase B: chromatographically pure acetonitrile. Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • Chromatographic column 1 A C18 silica packed 5 ⁇ m particle size stationary phase chromatography column is used as the preparation column. The diameter and length of the column are: 15cm ⁇ 25cm.
  • the first step mobile phase: A1 phase: 100mmol / L ammonium sulfate solution was adjusted to pH 2.8 with phosphoric acid; phase B: chromatographically pure acetonitrile. Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • the uraridide linear crude peptide solution was loaded and eluted in the following gradient: A1%: 85% -65%, B%: 15% -35%, and a total elution of 50-70min.
  • the products that meet the quality standards enter the second step.
  • the second step mobile phase: A2 phase: 0.1-0.4% ammonium acetate solution, pH 6.5-7.0, phase B: chromatographically pure acetonitrile. Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • Chromatographic column A stationary phase chromatographic column with a particle size of 10 ⁇ m on a C18 silica gel packing was used as the preparation column 1. The diameter and length of the column were 15 cm ⁇ 15 cm. A C18 silica packed 10 ⁇ m particle size stationary phase chromatography column was used as the preparation column 2. The diameter and length of the column were 15 cm ⁇ 10 cm.
  • the first step mobile phase: A1 phase: 100mmol / L ammonium sulfate solution was adjusted to pH 2.8 with phosphoric acid; phase B: chromatographically pure acetonitrile. Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • the uraridide linear crude peptide solution was loaded and eluted in the following gradient: A1%: 85% -65%, B%: 15% -35%, and a total elution of 50-70min.
  • the impurity peak waste liquid is treated, and when the target product is out of the peak, it is diluted online into the column 2 by a third pump connected to the tee mixer for secondary separation.
  • the mobile phase diluted online was purified water with a flow rate of 45-100 ml / min.
  • the product that meets the quality requirements after cyclic purification is entered into the second step.
  • the second step mobile phase: A2 phase: 0.1-0.4% ammonium acetate solution, pH 6.5-7.0, phase B: chromatographically pure acetonitrile. Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • Chromatographic column A stationary phase chromatographic column with a particle size of C18 silica gel 5 ⁇ m is used as the preparation column 1. The diameter and length of the column are: 15cm ⁇ 15cm. A C18 silica gel 5 ⁇ m particle size stationary phase chromatography column was used as the preparative column 2. The diameter and length of the column were 15 cm ⁇ 10 cm.
  • the first step mobile phase: A1 phase: 100mmol / L ammonium sulfate solution was adjusted to pH 2.8 with phosphoric acid; phase B: chromatographically pure acetonitrile. Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • the uraridide linear crude peptide solution was loaded and eluted in the following gradient: A1%: 85% -65%, B%: 15% -35%, and a total elution of 50-70min.
  • the impurity peak waste liquid is treated, and when the target product is out of the peak, it is diluted online by a third pump connected to the tee mixer to enter column 2 for secondary separation.
  • the mobile phase diluted online was purified water with a flow rate of 45-100 ml / min.
  • the product that meets the quality requirements after cyclic purification is entered into the second step.
  • the second step mobile phase: A2 phase: 0.1-0.4% ammonium acetate solution, pH 6.5-7.0, phase B: chromatographically pure acetonitrile. Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • Chromatographic column A stationary phase chromatographic column with a particle size of 10 ⁇ m of C8 silica gel was used as the preparation column 1. The diameter and length of the column were: 15 cm ⁇ 10 cm. A C4 silica gel 5 ⁇ m particle size stationary phase chromatography column was used as the preparation column 2. The diameter and length of the column were 15 cm ⁇ 10 cm.
  • the first step mobile phase: mobile phase: A1 phase: 100mmol / L ammonium bicarbonate solution was adjusted to pH 8.0 with tetramethylammonium hydroxide; phase B: chromatographically pure acetonitrile: isopropanol (9: 1). Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • the crude Samoglutide solution was loaded and eluted in the following gradient: A1%: 85% -65%, B%: 15% -35%, and a total elution of 50-70min.
  • the impurity peak waste liquid is treated, and when the target product is out of the peak, it is diluted online by a third pump connected to the tee mixer to enter column 2 for secondary separation.
  • the mobile phase diluted online was purified water with a flow rate of 50-70 ml / min.
  • the product that meets the quality requirements after cyclic purification is entered into the second step.
  • the second step mobile phase: A2 phase: 0.1-0.4% ammonium acetate solution, pH 6.5-7.0, phase B: chromatographically pure acetonitrile. Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • the preparative column 1 is washed with a acetonitrile solution of more than 50%, and then loaded, and washed with a 0.1-0.4% ammonium acetate solution (pH 6.5-7.0) containing 5% acetonitrile for 15-30 minutes, and finally washed with a gradient Deacetate, acetonitrile gradient: B%: 40% -60%, 40min, collect the peak of interest, and concentrate the collected peptide solution of solution at a water temperature of not more than 32 ° C under reduced pressure to about 15-50mg / mL and transfer to a suitable size The vial. After freeze-drying, Samo Lutai with a purity greater than 99.0% can be obtained. .
  • Chromatographic column A stationary phase chromatographic column with a particle size of 10 ⁇ m on a C18 silica gel packing was used as the preparation column 1. The diameter and length of the column were 15 cm ⁇ 15 cm. A C4 silica gel 5 ⁇ m particle size stationary phase chromatography column was used as the preparation column 2. The diameter and length of the column were 15 cm ⁇ 15 cm.
  • the first step mobile phase: mobile phase: A1 phase: 100mmol / L ammonium bicarbonate solution was adjusted to pH 8.0 with ammonia; phase B: chromatographically pure acetonitrile: isopropanol (9: 2). Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • the liraglutide crude peptide solution was loaded and eluted in the following gradient: A1%: 70% -55%, B%: 30% -45%, and a total elution of 50-70min.
  • the impurity peak waste liquid is treated, and when the target product peaks out, it is diluted online by a third pump connected to the tee and then enters column 2 for secondary separation.
  • the mobile phase diluted online was purified water with a flow rate of 50-100 ml / min.
  • the product that meets the quality requirements after cyclic purification is entered into the second step.
  • the second step mobile phase: A2 phase: 0.1-0.4% ammonium acetate solution, pH 6.5-6.8, phase B: chromatographically pure acetonitrile. Flow rate: 450-550ml / min. Detection wavelength: 230nm.
  • the preparative column 1 is washed with a acetonitrile solution of more than 50%, and then loaded, and washed with a 0.1-0.4% ammonium acetate solution containing 5% acetonitrile for 15-30 minutes, and finally eluted with a gradient, acetonitrile gradient: B% : 40% -60%, 30 minutes, the target peak is collected, and the collected target peptide solution is concentrated under reduced pressure to about 50 mg / mL by rotary evaporation under reduced pressure to about 50 mg / mL, and then transferred to a suitable size vial. After freeze-drying, liraglutide with a purity of more than 99.0% can be obtained. .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了一种长链多肽的纯化方法，其包括步骤1)，即纯化步骤：采用两根色谱柱串联进行粗品的分离，其中，上游色谱柱中填料的粒径比下游色谱柱填料粒径大；可选地，还包括作为转盐的步骤2)：采用步骤1)中的上游色谱柱进行转盐，将步骤1)得到的目标峰产物进行上样；以95％-85％的A2和5％-15％的B冲洗15-30min进行脱盐，其中，A2相为体积比0.05％-0.2％的醋酸水溶液，B相为有机相乙腈，检测波长为230nm。

Description

一种长链多肽的纯化方法 技术领域
本发明涉及药物分析领域，具体涉及一种长链多肽药物的纯化方法。
背景技术
Ularitide(乌拉立肽)是一种是由Cardiorentis(AG)开发的促尿钠***环肽，它由32个氨基酸残基，最初是在1988年由Schulz-Knappe等从尿液中分离得到的一种属于心房钠尿肽(atrialnatriureticpeptide，ANP)家族的肾利钠肽，主要用于治疗急性心力衰竭。
分子式如下：
Figure PCTCN2018089034-appb-000001
流行病学资料显示，目前全球心衰患者的数量已高达2250万，并且仍以每年200万的速度递增。且5年存活率与恶性肿瘤相仿，20％的心衰患者出院将在30天内再住院，花费了大量医疗费用。我国成年人心衰的患病率为0.9％，其中男性为0.7％，女性为1.0％，目前35～74岁成年人中仍约有400万的心衰患者，并呈逐年上升趋势。常见病因包括冠心病、高血压、心肌病和(或)瓣膜病、糖尿病等，其中冠脉疾病是心力衰竭的重要原因。据统计，全球每年花费在心衰上的资金为1080亿美元，2003年一项大型流行病学调查显示，中国内地成年人心衰患病率已达0.9％，约有心衰患者450万人。心衰分急性心衰和慢性心衰，美国过去10年中，因急性心衰而急诊就医者达1千万例次。急性心衰患者中约15～20％为首诊心衰，大部分则为原有的心衰加重，所有引起慢性心衰的疾病都可导致急性心衰。随慢性心衰患者数量逐渐增加，慢性心功能失代偿和急性心衰发作，也已成为心衰患者住院的主因，每年心衰的总发病率为0.23％～0.27％。急性心衰预后很差，住院病死率为3％，60d病死率为9.6％，3年和5年病死率分别高达30％和60％。急性心肌梗死所致的急性心衰病死率更高。急性肺水肿患者的院内病死率为12％，1年病死率达30％，所以乌拉立肽市场前景广阔。
现有多肽纯化，主要是采用高效液相制备***制备，有机相为乙腈、甲醇等，使用量较大，废液排放量也较大。废液回收难处理，危险性也较大，随着肽序的 延长，废液排放量将会更庞大，纯化周期也相应变长，企业成本也较大。环保、安全和成本问题已经制约着制药企业的发展，急需要一种降低企业成本和废液排放量的纯化方法，最大限度的降低有机废液储存中的危险性。
乌拉立肽主要用于急性心衰，所以质量显得尤为重要。乌拉立肽肽序较长，中间还要经过一步氧化，杂质更多，为了提高药物的安全性，现有多肽药物纯度要求也越高越好，大多要求纯度大于99％，并需对单杂进行控制，要求单杂小于0.10％，传统纯化过程达到此标准，一般需要经过两步纯化，一步转盐，收率将会特别低；人力成本、环境成本以及产品成本都将较大。
对于多肽的纯化主要是通过反相色谱纯化，采用的固定相一般包括C18，C8，C4，C1等等，另外就是最近有些项目采用聚合物填料进行纯化甚至其它反相填料，但无论采用何种类型的填料，纯化的过程基本无变化，基本过程有2种，一种通过高压填装同种填料制备柱，柱长一般25cm左右，粒径大多为10μm，然后通过不同的色谱条件进行纯化，然后对不合格部分进行回收，最终获得合格的产品，另一种为高压填装不同类型填料的制备柱，通过柱长为25cm左右，粒径一般为10μm，然后通过不同的色谱条件进行纯化，然后对不合格部分进行回收纯化，最终获得合格的产品，对于肽序较短的多肽，以上两种方式一般经过一步纯化即可完成，而对于肽序大于25个氨基酸的多肽产品，基本需要两步纯化，加上脱盐或转盐，共需要三步才可以完成，两种方式的缺点就是规模放大后，周期较长，另不合格中间体需要经过多次回收才能得到合格产品，因为需要回收纯化，周期延长，有机溶剂使用量变大，废液排放也变多，最终产品的成本变高，质量风险和有机溶剂危险系数也变大。
发明内容
本发明提供了一种新的纯化方法，可以提高产品的纯度，纯度大于99％，单杂小于0.10％，并可以大大降低成本和环保压力。
本发明提供了一种新纯化方法，区别于传统纯化方法，可以弥补传统纯化多次回收成本增加，周期较长，废液排放量大缺点，大大提高收率，并且易于放大生产。
本发明一个方面提供一种长链多肽的纯化方法，其包括如下步骤：
1)纯化步骤：采用两根色谱柱串联进行粗品的分离；
步骤1)色谱柱填料选自C18硅胶填料、C8硅胶填料、C4硅胶填料和聚合物填料；上游色谱柱的长度为8-20cm；下游色谱柱的长度8-20cm；
步骤1)流动相：A1相为缓冲盐溶液，其pH值为2-3，优选地，所述缓冲盐溶液为硫酸铵、磷酸二氢钾、磷酸氢二钠、磷酸氢二钾中的一种或几种；B相为有机相，所述的有机相为乙腈、甲醇、异丙醇和乙醇；缓冲盐物质的量浓度为20mM-150mM检测波长：230nm；
步骤1)包括以梯度洗脱：A1％：95％-55％，B％：5％—45％，洗脱时间为30-120分钟；在洗脱过程中，当上游色谱柱的流出峰为杂质峰时弃去相应的流动相，当上游色谱柱的流出峰为目标峰时启动在上下游色谱柱中间设置的三通混合器所连接的色谱泵，输入10％纯化水，降低流动相中有机相比例，进行在线稀释，在线稀释后进入下游色谱柱；
可选地，还包含作为转盐的步骤2)：
步骤2)采用步骤1)中的上游色谱柱进行转盐，A2相为体积比0.05％-0.2％的醋酸水溶液；B相为有机相，所述的有机相为乙腈、甲醇、异丙醇和乙醇；检测波长：230nm；
步骤2)包括：将步骤1)得到的目标峰产物进行上样；以95％A2和5％的B冲洗15-30min进行脱盐；
然后以梯度洗脱进行转盐，A2％：95％-55％，B％：5％-45％，洗脱10-30min，收集目标产物。
在本发明的技术方案中，所述的长链多肽选自35个氨基酸以上的长链多肽，优选为乌拉立肽、利拉鲁肽、萨摩鲁肽、胸腺法新、阿巴帕肽、利西拉肽等。
在本发明的技术方案中，步骤1)中上游色谱柱填料为10μm的C18硅胶填料，长度为10-15cm，第二色谱柱为5μm的C18硅胶填料，长度为10-15cm。
在本发明的技术方案中，步骤1)包括以梯度洗脱：A1％：85％-65％，B％：15％—55％，洗脱时间为50-70分钟。
在本发明的技术方案中，A1相pH值为2.2-2.8。
在本发明的技术方案中，A2相为体积比0.1％-0.4％的醋酸铵溶液。
在本发明的技术方案中，步骤2)以95％A2和5％B冲洗15-30min进行脱盐。
在本发明的技术方案中，步骤2)以梯度洗脱进行转盐，A2％：85％-65％， B％：15％-35％，洗脱10-30min，收集目标产物。
在本发明的技术方案中，所述的在线稀释为目标峰进入下游色谱柱前，经过第三泵输入10％纯化水，降低有机相比例。
一种新的纯化方法，同时装两根不同类型的色谱柱，第一制备柱为10μm C18，第二制备柱为5μm C18，考虑柱压、柱效以及填料综合成本，柱长均为10-15cm，然后串联，对于乌拉立肽纯化，粒径较大者在前，粒径较小者在后，然后将乌拉立肽氧化液上样纯化，经过纯化转盐后的得到乌拉立肽精肽。
一种新的乌拉立肽的纯化方法，采用两种不同类型的填料填装两根制备柱，然后串联，分一步纯化和一步转盐，第一步以一定浓度、一定pH缓冲盐溶液为A1相，以乙腈为B相，第二步以一定浓度醋酸为A2相，以乙腈为B相，梯度洗脱的HPLC方法转盐，收集溶液冻干即得到醋酸乌拉立肽。
乌拉立肽肽链较长，合成产生杂质较多，并且含有如Ser等合成过程中易异构化的氨基酸而导致粗肽中具有异构体杂质。本发明通过新的纯化方法，可以将两种不同类型填料进行串联纯化，利用两种不同类型填料、不同的分离能力的特点，第一制备柱进行纯化后，目标峰不流出制备***，进入下游色谱柱前，经过第三泵输入10％纯化水，降低有机相比例，然后接进入第二制备柱进行二次分离，原先需要两步纯化的过程，一步纯化完成，还减少了中间体处理过程、中间体存储引起的析出、变性等其它影响产品质量风险，省时省力，本纯化方法可以将粗肽中的异构体杂质和其它难分离杂质很好的分离而去除，然后利用反相HPLC方法转成醋酸盐，最终提高了产品的收率和纯度，同时解决传统纯化方法费时费力污染重的缺点，操作简便，有利于实现规模化的制备，并提供了一种新思路的纯化方法。
作为优选，本发明所述HPLC方法的流动相A1中缓冲盐物质的量浓度为20mM—150mM，流动相A2中醋酸的体积比为0.05％-0.2％。
作为优选，本发明所述HPLC方法的流动相A1中pH的范围为2.2-2.8。
其中，作为优选，所述缓冲盐为硫酸铵、磷酸二氢钾、磷酸氢二钠、磷酸氢二钾中的一种或几种。
作为优选，本发明所述纯化HPLC方法的流动相B的乙腈。
作为优选，本发明所述纯化HPLC方法的固定相为十八烷基，粒径为5μm和10μm。
有益效果
串联制备柱纯化是利用两种不同分离能力的填料进行纯化，在原有柱长度的情况下，实现两次分离，减少了回收次数，减少了周期，减少了有机相的使用量，并且操作简单，易于放大，最主要的是省时省力，节约成本，特别对于肽链长度大于35的多肽，因需要多步纯化并回收，效果将会更突出，主要是因为肽链越长，其疏水性增强，洗脱时有机相使用量增大，加上多次回收，所以废液量特别大。
实施例如下：
纯化规模包括以下规格色谱柱：5cm×25cm(柱子直径×长度)、10cm×25cm、15cm×25cm。
附图说明
图1为线性粗肽质谱结果。
图2为精肽质谱结果。
图3为实施例1纯品的HPLC结果。
图4为实施例2纯品的HPLC结果。
图5为实施例3纯品的HPLC结果。
图6为实施例4纯品的HPLC结果。
图7为实施例5纯品的HPLC结果。
图8为实施例6纯品的HPLC结果。
图9为实施例7纯品的HPLC结果。
图10为实施例8纯品的HPLC结果。
图11为实施例9纯品的HPLC结果。
具体实施方式
实施例1：乌拉立肽粗肽纯化
将乌拉立肽线性粗肽2.0g溶解过滤，收集滤液备用。
1、纯化条件：色谱柱：以C18硅胶填料10μm粒径的固定相色谱柱为制备柱1，柱子直径和长度为：5cm×10cm。以C18硅胶填料5μm粒径的固定相色谱柱为制备柱2，柱子直径和长度为：5cm×15cm。
第一步：流动相：A1相：50mmol/L的磷酸二氢钾溶液用磷酸调pH至2.2；B相：色谱纯乙腈。流速：60-80ml/min。检测波长：230nm。
将乌拉立肽线性粗肽溶液上样，并以以下梯度进行洗脱：A1％：85％-65％，B％：15％—35％，共洗脱50-70min。洗脱过程中经过色谱柱1分离时，杂质峰废液处理，在目标产物出峰时经过三通混合器连接的第三泵在线稀释后进入柱2，进行二次分离。
在线稀释的流动相为纯化水，流速为5-20ml/min。
第一步循环纯化后，符合质量要求的目标产物，进入第二步。
第二步：流动相：A2相：0.1-0.4％的醋酸铵溶液，pH值为6.5-7.0，B相：色谱纯乙腈。流速：60-80ml/min。检测波长：230nm。
将制备柱1用50％以上的乙腈溶液冲洗干净后上样步骤1得到的产品，以95％A2和5％B冲洗15-30min进行脱盐。然后以梯度洗脱进行转盐，A2％：85％-65％，B％：15％-35％，洗脱20min，收集目的峰。将收集的目的肽溶液于水温不超过32℃下减压旋蒸浓缩至约15-50mg/mL后转至合适大小西林瓶。冷冻干燥后即可得到纯度大于99.0％的符合标准的乌拉立肽。
冻干后得白色粉末状固体精肽0.92g。纯度99.28％，单个杂质均小于0.15％。纯化收率68％(以粗品中乌拉立肽含量计算)，总收率46％，纯化过程中，不需要对中间体进行回收纯化，经过计算，相对于实施例4-5，由于第一步循环次数降低，纯化单位质量的乌拉力肽粗肽的废液排放减少约30％。
实施例2：乌拉立肽粗肽纯化
将乌拉立肽粗肽15g溶解过滤，收集滤液备用。
1、纯化条件：色谱柱：以C18硅胶填料10μm粒径的固定相色谱柱为制备柱1，柱子直径和长度为：10cm×15cm。以C18硅胶填料5μm粒径的固定相色谱柱为制备柱2，柱子直径和长度为：10cm×10cm。
第一步：流动相：A1相：150mmol/L的磷酸二氢钾溶液用磷酸调pH至2.5；B相：色谱纯乙腈。流速：200-220ml/min。检测波长：230nm。
将乌拉立肽线性粗肽溶液上样，并以以下梯度进行洗脱：A1％：85％-65％，B％：15％-35％，共洗脱50-70min。洗脱过程中经过色谱柱1分离时，杂质峰废液处理，在目标产物出峰时经过三通混合器连接的第三泵在线稀释后进入柱2，进行二次分离。
在线稀释的流动相为纯化水，流速为20-50ml/min。
第一步循环纯化后，符合质量标准的产物，进入第二步。
第二步：流动相：A2相：0.1-0.4％的醋酸铵溶液，pH值为6.5-7.0，B相：色谱纯乙腈。流速：200-220ml/min。检测波长：230nm。
将制备柱1用50％以上的乙腈溶液冲洗干净后上样步骤1得到的产品，以95％A2和5％B冲洗15-30min进行脱盐。然后以梯度洗脱进行转盐，A2％：85％-65％，B％：15％-35％，20min，收集目的峰，将收集的目的肽溶液于水温不超过32℃下减压旋蒸浓缩至约15-50mg/mL后转至合适大小西林瓶。冷冻干燥后即可得到纯度大于99.0％的符合标准的乌拉立肽。
冻干后得白色粉末状固体精肽7.1g。纯度99.30％，单个杂质均小于0.10％。纯化收率73.9％(以粗品中乌拉立肽含量计算)，总收率47.3％，经过计算，相对于实施例4-5，由于第一步循环次数降低，纯化单位质量的乌拉力肽粗肽的废液排放减少约35％。
实施例3：乌拉立肽粗肽纯化
将乌拉立肽粗肽25g溶解过滤，收集滤液备用。
1、纯化条件：色谱柱：以C18硅胶填料10μm粒径的固定相色谱柱为制备柱1，柱子直径和长度为：15cm×15cm。以C18硅胶填料5μm粒径的固定相色谱柱为制备柱2，柱子直径和长度为：15cm×10cm。
第一步：流动相：A1相：100mmol/L的硫酸铵溶液用磷酸调pH至2.8；B相：色谱纯乙腈。流速：450-550ml/min。检测波长：230nm。
将乌拉立肽线性粗肽溶液上样，并以以下梯度进行洗脱：A1％：85％-65％，B％：15％—35％，共洗脱50-70min。洗脱过程中经过色谱柱1分离时，杂质峰废液处理，在目标产物出峰时经过三通混合器连接的第三泵在线稀释后进入柱2，进行二次分离。
在线稀释的流动相为纯化水，流速为45-100ml/min。
第一步循环纯化后符合质量要求的产物，进入第二步。
第二步：流动相：A2相：0.1-0.4％的醋酸铵溶液，pH值为6.5-7.0，B相：色谱纯乙腈。流速：450-550ml/min。检测波长：230nm。
将制备柱1用50％以上的乙腈溶液冲洗干净后上样步骤1得到的产品，以95％A2和5％B冲洗15-30min进行脱盐。然后以梯度洗脱进行转盐，A2％： 85％-65％，B％：15％-35％，洗脱20min，收集目的峰。将收集的目的肽溶液于水温不超过32℃下减压旋蒸浓缩至约15-50mg/mL后转至合适大小西林瓶。冷冻干燥后即可得到纯度大于99.0％的符合标准的乌拉立肽。
冻干后得白色粉末状固体精肽12.1g。纯度99.26％，单个杂质均小于0.10％。纯化收率67％(以粗品中乌拉立肽含量计算)，48.4％，经过计算，相对于实施例4-5，由于第一步循环次数降低，纯化单位质量的乌拉力肽粗肽的废液排放减少约40％。
实施例4：乌拉立肽粗肽纯化对照例
将乌拉立肽粗肽25g溶解过滤，收集滤液备用。
1、纯化条件：色谱柱：以C18硅胶填料10μm粒径的固定相色谱柱为制备柱1，柱子直径和长度为：15cm×25cm。
第一步：流动相：A1相：100mmol/L的硫酸铵溶液用磷酸调pH至2.8；B相：色谱纯乙腈。流速：450-550ml/min。检测波长：230nm。
将乌拉立肽线性粗肽溶液上样，并以以下梯度进行洗脱：A1％：85％-65％，B％：15％—35％，共洗脱50-70min。
第一步循环后符合质量标准的产物，进入第二步。
第二步：流动相：A2相：0.1-0.4％的醋酸铵溶液，pH值为6.5-7.0，B相：色谱纯乙腈。流速：450-550ml/min。检测波长：230nm。
将制备柱1用50％以上的乙腈溶液冲洗干净后上样步骤1得到的产品，以95％A2和5％B冲洗15-30min进行脱盐。然后以梯度洗脱进行转盐，A2％：85％-65％，B％：15％-35％，洗脱20min，收集目的峰。将收集的目的肽溶液于水温不超过32℃下减压旋蒸浓缩至约15-50mg/mL后转至合适大小西林瓶。冷冻干燥后即可得到纯度大于99.0％的符合标准乌拉立肽。
冻干后得白色粉末状固体精肽8.1g。纯度99.30％，单个杂质均小于0.10％。纯化收率64％(以粗品中乌拉立肽含量计算)，总收率32.4％，经过计算，25克粗肽纯化时，不合格馏分需要至少3次回收纯化后才与实施例1所得的结果相同，车间放大后，不合格馏分回收次数至少增加30％～40％，乙腈用量多20～30％，废液排放多约40％，周期多30％。
实施例5：乌拉立肽粗肽纯化对照例
将乌拉立肽粗肽25g溶解过滤，收集滤液备用。
1、纯化条件：色谱柱1：以C18硅胶填料5μm粒径的固定相色谱柱为制备柱，柱子直径和长度为：15cm×25cm。
第一步：流动相：A1相：100mmol/L的硫酸铵溶液用磷酸调pH至2.8；B相：色谱纯乙腈。流速：450-550ml/min。检测波长：230nm。
将乌拉立肽线性粗肽溶液上样，并以以下梯度进行洗脱：A1％：85％-65％，B％：15％—35％，共洗脱50-70min。
第一步循环后符合质量标准的产物，进入第二步。
第二步：流动相：A2相：0.1-0.4％的醋酸铵溶液，pH值为6.5-7.0，B相：色谱纯乙腈。流速：450-550ml/min。检测波长：230nm。
将制备柱1用50％以上的乙腈溶液冲洗干净后上样步骤1得到的产品，以95％A2和5％B冲洗15-30min进行脱盐。然后以梯度洗脱进行转盐，A2％：85％-65％，B％：15％-35％，洗脱20min，收集目的峰，将收集的目的肽溶液于水温不超过32℃下减压旋蒸浓缩至约15-50mg/mL后转至合适大小西林瓶。冷冻干燥后即可得到纯度大于99.0％的符合标准乌拉立肽。
冻干后得白色粉末状固体精肽8.3g。纯度99.30％，单个杂质均小于0.10％。纯化收率64％(以粗品中乌拉立肽含量计算)，总收率33.2％，经过计算，乙腈用量多15％，废液排放多约35％，周期多20％，但制备过程中，馏分储存过程中析出，溶解难度较大，并且制备时，柱压较高，接近制备***的上限，不建议使用5μm的反相填料进行制备，填料成本也较高。
实施例6：乌拉立肽粗肽纯化对照例
将乌拉立肽粗肽25g溶解过滤，收集滤液备用。
1、纯化条件：色谱柱：以C18硅胶填料10μm粒径的固定相色谱柱为制备柱1，柱子直径和长度为：15cm×15cm。以C18硅胶填料10μm粒径的固定相色谱柱为制备柱2，柱子直径和长度为：15cm×10cm。
第一步：流动相：A1相：100mmol/L的硫酸铵溶液用磷酸调pH至2.8；B相：色谱纯乙腈。流速：450-550ml/min。检测波长：230nm。
将乌拉立肽线性粗肽溶液上样，并以以下梯度进行洗脱：A1％：85％-65％，B％：15％—35％，共洗脱50-70min。洗脱过程中经过色谱柱1分离时，杂质峰废液处理，在目标产物出峰时经过三通混合器连接的第三泵在线稀释进入柱2，进行二次分离。
在线稀释的流动相为纯化水，流速为45-100ml/min。
第一步循环纯化后符合质量要求的产物，进入第二步。
第二步：流动相：A2相：0.1-0.4％的醋酸铵溶液，pH值为6.5-7.0，B相：色谱纯乙腈。流速：450-550ml/min。检测波长：230nm。
将制备柱1用50％以上的乙腈溶液冲洗干净后上样步骤1得到的产品，以95％A2和5％B冲洗15-30min进行脱盐。然后以梯度洗脱进行转盐，A2％：85％-65％，B％：15％-35％，洗脱20min，收集目的峰。将收集的目的肽溶液于水温不超过32℃下减压旋蒸浓缩至约15-50mg/mL后转至合适大小西林瓶。冷冻干燥后即可得到纯度大于99.0％的符合标准的乌拉立肽。
冻干后得白色粉末状固体精肽8.52g。纯度99.24％，单个杂质均小于0.10％。纯化收率64％(以粗品中乌拉立肽含量计算)，34.1％，经过计算，相对于实施例4，由于第一步循环降低10％左右，纯化单位质量的乌拉力肽粗肽的废液排放减少约5％。粒径较大时，串联同种色谱填料优势不明显。
实施例7：乌拉立肽粗肽纯化对照例
将乌拉立肽粗肽25g溶解过滤，收集滤液备用。
1、纯化条件：色谱柱：以C18硅胶填料5μm粒径的固定相色谱柱为制备柱1，柱子直径和长度为：15cm×15cm。以C18硅胶填料5μm粒径的固定相色谱柱为制备柱2，柱子直径和长度为：15cm×10cm。
第一步：流动相：A1相：100mmol/L的硫酸铵溶液用磷酸调pH至2.8；B相：色谱纯乙腈。流速：450-550ml/min。检测波长：230nm。
将乌拉立肽线性粗肽溶液上样，并以以下梯度进行洗脱：A1％：85％-65％，B％：15％—35％，共洗脱50-70min。洗脱过程中经过色谱柱1分离时，杂质峰废液处理，在目标产物出峰时经过三通混合器连接的第三泵在线稀释后进入柱2，进行二次分离。
在线稀释的流动相为纯化水，流速为45-100ml/min。
第一步循环纯化后符合质量要求的产物，进入第二步。
第二步：流动相：A2相：0.1-0.4％的醋酸铵溶液，pH值为6.5-7.0，B相：色谱纯乙腈。流速：450-550ml/min。检测波长：230nm。
将制备柱1用50％以上的乙腈溶液冲洗干净后上样步骤1得到的产品，以95％A2和5％B冲洗15-30min进行脱盐。然后以梯度洗脱进行转盐，A2％： 85％-65％，B％：15％-35％，洗脱20min，收集目的峰。将收集的目的肽溶液于水温不超过32℃下减压旋蒸浓缩至约15-50mg/mL后转至合适大小西林瓶。冷冻干燥后即可得到纯度大于99.0％的符合标准的乌拉立肽。
冻干后得白色粉末状固体精肽8.9g。纯度99.24％，单个杂质均小于0.10％。纯化收率66％(以粗品中乌拉立肽含量计算)，35.6％，经过计算，相对于实施例5，由于采用相同的小粒径后，有些杂质去除效果变好，有些杂质去除反而变弱，总体折算，第一步循环次数降低20％左右，纯化单位质量的乌拉力肽粗肽的废液排放减少约15％。但是填料成本升高30％，总体折算，优势不明显。
实施例8：萨摩鲁肽粗肽纯化
将萨摩鲁肽粗肽15g溶解过滤，收集滤液备用。
1、纯化条件：色谱柱：以C8硅胶填料10μm粒径的固定相色谱柱为制备柱1，柱子直径和长度为：15cm×10cm。以C4硅胶填料5μm粒径的固定相色谱柱为制备柱2，柱子直径和长度为：15cm×10cm。
第一步：流动相：流动相：A1相：100mmol/L碳酸氢铵溶液用四甲基氢氧化铵调pH至8.0；B相：色谱纯乙腈：异丙醇(9：1)。流速：450-550ml/min。检测波长：230nm。
将萨摩鲁肽粗肽溶液上样，并以以下梯度进行洗脱：A1％：85％-65％，B％：15％—35％，共洗脱50-70min。洗脱过程中经过色谱柱1分离时，杂质峰废液处理，在目标产物出峰时经过三通混合器连接的第三泵在线稀释后进入柱2，进行二次分离。
在线稀释的流动相为纯化水，流速为50-70ml/min。
第一步循环纯化后符合质量要求的产物，进入第二步。
第二步：流动相：A2相：0.1-0.4％的醋酸铵溶液，pH值为6.5-7.0，B相：色谱纯乙腈。流速：450-550ml/min。检测波长：230nm。
将制备柱1将色谱柱用50％以上的乙腈溶液冲洗干净后上样，用含5％乙腈的0.1-0.4％的醋酸铵溶液(pH为6.5-7.0)冲洗15-30min，最后用梯度洗脱，乙腈梯度：B％：40％—60％，40min，收集目的峰，将收集的目的肽溶液于水温不超过32℃下减压旋蒸浓缩至约15-50mg/mL后转至合适大小西林瓶。冷冻干燥后即可得到纯度大于99.0％的符合标准萨摩鲁泰。。
冻干后得白色粉末状固体精肽4.1g。纯度99.32％，单个杂质均小于0.15％。 纯化收率57％(以粗品中萨摩鲁泰含量计算)，总收率27.3％。经过串联后，废液排放减少35％，周期减少25％。
实施例9：利拉鲁肽粗肽纯化
将利拉鲁肽粗肽15g溶解过滤，收集滤液备用。
1、纯化条件：色谱柱：以C18硅胶填料10μm粒径的固定相色谱柱为制备柱1，柱子直径和长度为：15cm×15cm。以C4硅胶填料5μm粒径的固定相色谱柱为制备柱2，柱子直径和长度为：15cm×15cm。
第一步：流动相：流动相：A1相：100mmol/L碳酸氢铵溶液用氨水调pH至8.0；B相：色谱纯乙腈：异丙醇(9：2)。流速：450-550ml/min。检测波长：230nm。
将利拉鲁肽粗肽溶液上样，并以以下梯度进行洗脱：A1％：70％-55％，B％：30％—45％，共洗脱50-70min。洗脱过程中经过色谱柱1分离时，杂质峰废液处理，在目标产物出峰时经过三通连接的第三泵在线稀释后进入柱2，进行二次分离。
在线稀释的流动相为纯化水，流速为50-100ml/min。
第一步循环纯化后符合质量要求的产物，进入第二步。
第二步：流动相：A2相：0.1-0.4％的醋酸铵溶液，pH值为6.5-6.8，B相：色谱纯乙腈。流速：450-550ml/min。检测波长：230nm。
将制备柱1将色谱柱用50％以上的乙腈溶液冲洗干净后上样，用含5％乙腈的0.1-0.4％的醋酸铵溶液冲洗15-30min，最后用梯度洗脱，乙腈梯度：B％：40％—60％，30min，收集目的峰，将收集的目的肽溶液于水温不超过32℃下减压旋蒸浓缩至约50mg/mL后转至合适大小西林瓶。冷冻干燥后即可得到纯度大于99.0％的符合标准利拉鲁肽。。
冻干后得白色粉末状固体精肽3.8g。纯度99.32％，单个杂质均小于0.15％。纯化收率52％(以粗品中利拉鲁肽含量计算)，总收率25.3％。经过串联后，废液排放减少30％，周期减少25％左右。

Claims (9)

  1. 一种长链多肽的纯化方法，其包括如下步骤：
    1)纯化步骤：采用两根色谱柱串联进行粗品的分离；
    步骤1)色谱柱填料选自C18硅胶填料、C8硅胶填料、C4硅胶填料和聚合物填料或者同种烷基长度不同孔径的填料；上游色谱柱的长度为8-20cm；下游色谱柱的长度8-20cm；
    步骤1)流动相：A1相为缓冲盐溶液，其pH值为2-3，优选地，所述缓冲盐溶液为硫酸铵、磷酸二氢钾、磷酸氢二钠、磷酸氢二钾中的一种或几种；B相为有机相，所述的有机相为乙腈、甲醇、异丙醇和乙醇；缓冲盐物质的量浓度为20mM-150mM，检测波长：230nm；
    步骤1)包括以梯度洗脱：A1％：95％-55％，B％：5％—45％，洗脱时间为30-120分钟；在洗脱过程中，当上游色谱柱的流出峰为杂质峰时弃去相应的流动相，当上游色谱柱的流出峰为目标峰时启动在上下游色谱柱中间设置的三通混合器所连接的色谱泵，输入纯化水，进行在线稀释，在线稀释后目标峰进入下游色谱柱；
    可选地，还包含作为转盐的步骤2)：
    步骤2)采用步骤1)中的上游色谱柱进行转盐，A2相为体积比0.05％-0.2％的醋酸水溶液；B相为有机相，所述的有机相为乙腈；检测波长：230nm；
    步骤2)包括：将步骤1)得到的目标峰产物进行上样；以95％A2和5％的B冲洗15-30min进行脱盐；
    然后以梯度洗脱进行转盐，A2％：95％-55％，B％：5％-45％，洗脱10-30min，收集目标产物。
  2. 根据权利要求1所述的纯化方法，所述的长链多肽选自35个氨基酸以上的长链多肽，优选为乌拉立肽、利拉鲁肽、萨摩鲁肽、胸腺法新、阿巴帕肽、利西拉肽。
  3. 根据权利要求1所述的纯化方法，步骤1)中上游色谱柱填料为10μm的C18胶填料，长度为10-15cm，第二色谱柱为5μm的C18硅胶填料，长度为10-15cm。
  4. 根据权利要求1所述的纯化方法，步骤1)包括以梯度洗脱：A1％：85％-65％，B％：15％—55％，洗脱时间为50-70分钟。
  5. 根据权利要求1所述的纯化方法，所述的在线稀释为目标峰进入下游色谱柱前，经过第三泵输入10％纯化水，降低有机相比例。
  6. 根据权利要求1所述的纯化方法，A1相pH值为2.2-2.8。
  7. 根据权利要求1所述的纯化方法，A2相为体积比0.1％-0.4％的醋酸铵溶液。
  8. 根据权利要求1所述的纯化方法，步骤2)以95％A2和5％B冲洗15-30min进行脱盐。
  9. 根据权利要求1所述的纯化方法，步骤2)以梯度洗脱进行转盐，A2％：85％-65％，B％：15％-35％，洗脱10-30min，收集目标产物。
PCT/CN2018/089034 2018-05-30 2018-05-30 一种长链多肽的纯化方法 WO2019227342A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201880000485.0A CN110785427B (zh) 2018-05-30 2018-05-30 一种长链多肽的纯化方法
US15/733,862 US11312744B2 (en) 2018-05-30 2018-05-30 Method for purifying long chain polypeptide
EP18921212.9A EP3805246A4 (en) 2018-05-30 2018-05-30 METHODS OF PURIFICATION OF LONG-CHAIN POLYPEPTIDES
PCT/CN2018/089034 WO2019227342A1 (zh) 2018-05-30 2018-05-30 一种长链多肽的纯化方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/089034 WO2019227342A1 (zh) 2018-05-30 2018-05-30 一种长链多肽的纯化方法

Publications (1)

Publication Number Publication Date
WO2019227342A1 true WO2019227342A1 (zh) 2019-12-05

Family

ID=68697783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/089034 WO2019227342A1 (zh) 2018-05-30 2018-05-30 一种长链多肽的纯化方法

Country Status (4)

Country Link
US (1) US11312744B2 (zh)
EP (1) EP3805246A4 (zh)
CN (1) CN110785427B (zh)
WO (1) WO2019227342A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021129016A1 (zh) * 2019-12-27 2021-07-01 深圳翰宇药业股份有限公司 一种多肽脱盐的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113624898B (zh) * 2021-08-23 2023-08-25 成都诺和晟泰生物科技有限公司 一种手性镇痛类多肽药物的纯化方法
CN113683663A (zh) * 2021-09-16 2021-11-23 杭州信海医药科技有限公司 一种机体保护多肽粗品的纯化方法
CN114478750B (zh) * 2021-12-28 2024-04-02 深圳翰宇药业股份有限公司 一种特立帕肽的纯化方法
US11806387B1 (en) 2022-05-20 2023-11-07 Radius Health, Inc. Process of making abaloparatide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104371018A (zh) * 2014-01-22 2015-02-25 江苏汉邦科技有限公司 一种乌拉立肽的制备方法
CN105949284A (zh) * 2016-05-26 2016-09-21 吉尔生化（上海）有限公司 一种纯化西那普肽的方法
CN106519009A (zh) * 2016-10-26 2017-03-22 杭州固拓生物科技有限公司 一种乌拉立肽的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0763061B1 (de) * 1994-06-02 2002-10-30 Forssmann, Wolf-Georg, Prof. Dr. med. Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung
RU2332247C1 (ru) * 2007-06-01 2008-08-27 Закрытое акционерное общество "БиоХимМак СТ" Способ очистки иммуноглобулина (варианты)
CN104045557B (zh) * 2014-06-25 2015-10-21 上海华震科技有限公司 一种高纯度普伐他汀钠纯化工艺
US10859476B2 (en) * 2014-11-27 2020-12-08 Hunan Demeter Instruments Co., Ltd. Liquid phase chromatograph
US10690635B2 (en) * 2016-03-23 2020-06-23 Bachem Holding Ag Purification of glucagon-like peptide 1 analogs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104371018A (zh) * 2014-01-22 2015-02-25 江苏汉邦科技有限公司 一种乌拉立肽的制备方法
CN105949284A (zh) * 2016-05-26 2016-09-21 吉尔生化（上海）有限公司 一种纯化西那普肽的方法
CN106519009A (zh) * 2016-10-26 2017-03-22 杭州固拓生物科技有限公司 一种乌拉立肽的制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021129016A1 (zh) * 2019-12-27 2021-07-01 深圳翰宇药业股份有限公司 一种多肽脱盐的方法

Also Published As

Publication number Publication date
CN110785427A (zh) 2020-02-11
CN110785427B (zh) 2023-09-05
US11312744B2 (en) 2022-04-26
EP3805246A1 (en) 2021-04-14
US20210230216A1 (en) 2021-07-29
EP3805246A4 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
WO2019227342A1 (zh) 一种长链多肽的纯化方法
EP2813514B1 (en) Method for purifying solid-phase synthetic crude liraglutide
Yamashiro et al. Simultaneous Synthesis of 1-Hemi-D-cystine-oxytocin and Oxytocin and Separation of the Diastereoisomers by Partition Chromatography on Sephadex and by Countercurrent Distribution1
CN110540587B (zh) 一种有效提高合成肽纯化收率的色谱方法
CN112661815B (zh) 一种Tirzepatide的纯化方法
CN105777872A (zh) 一种萨摩鲁肽的纯化方法
CN114660214B (zh) 一种司美格鲁肽的液相色谱检测方法及其应用
WO2020108629A1 (zh) 一种多肽rdp1及其提纯方法与应用
WO2021232543A1 (zh) 一种利用超临界流体色谱***分离辅酶q10的方法
CN101555279A (zh) 一种高纯度尿促***及其制备方法
CN102219849A (zh) 一种大规模分离纯化艾塞那肽的方法
WO2018126524A1 (zh) 一种六胜肽的纯化方法
CN109053863A (zh) 一种低成本制备高纯度利那洛肽的方法
WO2020133993A1 (zh) 多肽的纯化方法
CN109748948B (zh) 一种棕榈酰四肽-7的纯化方法
WO2020114002A1 (zh) 一种glp-1类似多肽的纯化方法
WO2020147421A1 (zh) 一种舒更葡糖的分离纯化方法
WO2021129016A1 (zh) 一种多肽脱盐的方法
CN105949284A (zh) 一种纯化西那普肽的方法
CN105223296A (zh) 一类多肽的纯化方法
WO2021017793A1 (zh) 一种化学合成酸性多肽的制备方法
CN115006419A (zh) 拟人参皂苷f11在制备治疗心力衰竭药物中的应用、治疗心力衰竭的药物及制备方法
CN114478750A (zh) 一种特立帕肽的纯化方法
CN111848777A (zh) 纯化索玛鲁肽的方法
CN112500473A (zh) 一种醋酸艾塞那肽的分离纯化方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18921212

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018921212

Country of ref document: EP

Effective date: 20210111